A Study of SL-279252 in Patients with Advanced Solid Tumours

Trial ID: NCT03894618
Kidney Cancer Type: Any


SL-279252 is an experimental drug belonging to a new class of immunotherapies called “fusion proteins”. This means that the researchers have “fused” together two drugs to produce a single compound capable of targetting two different molecules with a single medication. This fusion protein works by targeting the molecules PD-L1 and OX40L.

Blocking PD-L1 serves to activate the body’s immune defences in order to target and destroy cancer cells. This is similar to a drug that is already used to treat Kidney Cancer, called Avelumab (Bavencio®).

Activating OX40L is a new approach to cancer treatment and may enhance the body’s immune response against cancerous cells by increasing the number of tumour-fighting white blood cells.

The Trial:
This study will investigate the safety and effectiveness of SL-279252 alone

In order to maximize effectiveness and minimize side effects, different doses of each drug will be used to determine the optimal dosage of these medications.

This is a single-group study, so there is no randomization, no placebo, and all patients will receive treatment.

Basic Eligibility:

  • All subtypes eligible
  • Advanced kidney cancer that cannot be removed by surgery
  • No further drug treatments are available or recommended

Additional eligibility criteria will apply. Please speak to your doctor.


Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentrePrincess Margaret Cancer Center Principal InvestigatorDr. Lillian Siu LocationToronto, ON Trial StatusRecruiting
Do NOT follow this link or you will be banned from the site!